News from IMIM
Oncologists from Hospital del Mar and IMIM have expanded and improved the genetic test for detecting the presence of mutations that frequently cause resistance to a treatment used against colon cancer. This genetic test, which had already been validated and incorporated into clinical practice in 2014, through an agreement with the Belgian company Biocartis, has now been expanded to include new mutations, allowing oncologists to improve and personalise colon cancer treatments still further.
This genetic test came into being in 2012 thanks to research work led by Dr. Clara Montagut and Dr. Joan Albanell. For the first time they identified a biomarker showing how the mutation in an oncogene, the epidermal growth factor receptor (EGFR), was the cause of the resistance to a drug group frequently used in colorectal cancer, the anti-EGFR drugs. This was the starting point for the subsequent marketing of a kit which contributes to personalised colon cancer treatments.
“This new set of resistance mutations enables us to improve patient care for colon cancer sufferers who are receiving anti-EGFR therapy. I am looking forward to the liquid biopsy version of this trial, which we are actively working towards. It will allow us to determine these mutations by analysing a patient's blood sample, and will give us a real-time view of how the tumour is behaving. It will help us monitor the tumour more closely and enable personalised therapeutic decisions to be made at all times”, explains Dr. Montagut.